Litcius/Paper detail

Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial

Yehuda Carmeli, José Miguel Cisneros, Mical Paul, George L. Daikos, Minggui Wang, Julián Torre‐Cisneros, George Singer, Ivan Titov, Illia Gumenchuk, Yongjie Zhao, R. Jiménez-Rodríguez, Lu Liang, Gang Chen, O. V. Pyptіuk, Firdevs Aksoy, Halley Rogers, Michele Wible, Francis F. Arhin, Alison Luckey, Joanne L. Leaney, Rienk Pypstra, Joseph W. Chow, Marc Bonten, Jesús Rodríguez‐Baño, Christine Lammens, Herman Goossens, Surbhi Malhotra‐Kumar

2024The Lancet Infectious Diseases102 citationsDOI

Topics & Concepts

AztreonamDescriptive statisticsGram-negative bacteriaCeftazidime/avibactamOpen labelMedicineGramMeropenemInternal medicineRandomized controlled trialMicrobiologyBacteriaBiologyStatisticsAntibioticsMathematicsGenePseudomonas aeruginosaAntibiotic resistanceBiochemistryGeneticsImipenemCeftazidimeEscherichia coliNosocomial Infections in ICUAntibiotic Resistance in BacteriaSepsis Diagnosis and Treatment
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial | Litcius